Potential role of endogenous adenosine in ticagrelor-induced dyspnea

Pharmacotherapy

Volumn 33, Issue 8, 2013, Pages 882-887

  Belchikov, Yuly G ^a,b   Koenig, Seth J ^c   DiPasquale, Elissa M ^d  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d Syosset Hospital   (United States)

Author keywords

Adenosine; C fibers; Dyspnea; Ticagrelor

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; CLOPIDOGREL; PLACEBO; PURINERGIC RECEPTOR; REGADENOSON; TICAGRELOR;

ARACHIDONIC ACID METABOLISM DISORDER; ASTHMA; BREATHING RATE; BRONCHOSPASM; COUGHING; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVITY; ENZYME INHIBITION; HEADACHE; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG VENTILATION; LUNG VOLUME; MAST CELL DEGRANULATION; METABOLIC DISORDER; NONHUMAN; OXYGEN SATURATION; OXYGENATION; PATIENT COMPLIANCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION;

EID: 84885196906     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1293     Document Type: Review

References (31)

1. Vandvik O, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e637S-68S.
2. Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev 2011;19:95-100.
3. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomised double blind study. Lancet 2010;375:283-93.
4. Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011;105:S75-81.
5. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51.
6. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
7. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93.
8. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945-53.
9. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185:435-52.
10. Lian EC. Pathogenesis of thrombotic thrombocytopenia purpura ADAMTS13 deficiency and beyond. Semin Thromb Hemost 2005;31:625-32.
11. Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007;61:529-33.
12. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 2001;91:133-47.
13. Siegel GJ, Agranoff BW, Albers RW, et al., eds. Basic neurochemistry: molecular, cellular and medical aspects, 6th ed. Philadelphia, PA: Lippincott-Raven, 1999:471-95.
14. Burnstock G. Purinergic nerves. Pharmacol Rev 1972;24:509-81.
15. Kiesman WF, Elziein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol 2009;193:25-58.
16. Burki NK, Lee LY. Blockade of airway sensory nerves and dyspnea in humans. Pulm Pharmacol Ther 2010;23:279-82.
17. Burki NK, Wheeler JD, Lee LY. Intravenous adenosine and dyspnea in humans. J Appl Physiol 2005;98:180-95.
18. Burki NK, Alam M, Lee LY. The pulmonary effects of intravenous adenosine in asthmatic subjects. Respir Res 2006;7:139.
19. Brown RA, Clarke GW, Ledbetter CL, et al. Elevated expression of adenosine A1 receptor in the bronchial biopsy specimens from asthmatic subjects. Eur Respir J 2008; 31:311-9.
20. Reynolds SM, Docherty R, Robbins J, Spina D. Adenosine induces a cholinergic tracheal reflex contraction in guinea pigs in vivo via an adenosine A1 receptor-dependent mechanism. J Appl Physiol 2008;105:187-96.
21. Kwong K, Hong JL, Morton RF, Lee LY. Role of pulmonary C fibers in adenosine-induced respiratory inhibition of anesthetized rats. J Appl Physiol 1998;84:417-24.
22. Basoglu OK, Pelleg A, Essilfie-Quaye S, Brindicci C, Barnes PJ, Kharitonov SA. Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 2005;128:1905-9.
23. Ohman J, Kudira R, Albinsson S, Olde B, Erlidnge D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012;418:754-8.
24. Balan KK, Critchley M. Is the dyspnea during adenosine cardiac stress test caused by bronchospasm? Am Heart J 2001;142:142-5.
25. Leaker BR, O'Connor B, Hansel TT, et al. Safety of regadenoson, and adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36.
26. Husted S, Emmanuelson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel and aspirin. Eur Heart J 2006;27:1038-47.
27. Garcia Puig J, Mateos FA. Clinical and biochemical aspects of uric acid overproduction. Pharm World Sci 1994;16:40-54.
28. Bjorkman J-A, Kirk I, van Giezen JJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion (abstract). Circulation 2007;116:II28.
29. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986;55:12-8.
30. Javadi H, Shariati M, Mogharrabi M, et al. The association of dipyridamole side effects with hemodynamic parameters, ECG findings, and scintigraphy outcomes. J Nucl Med Technol 2010;38:149-52.
31. Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808:1290-308.